Bioline Rx (BLRX) Stock Statistics & Valuation Metrics

Bioline Rx has a market cap or net worth of 63.94M. The enterprise value is 24.50M.

Bioline Rx has 2,557,611,000 shares outstanding. The number of shares has decreased by -2.65% in one year.

Bioline Rx’s return on equity (ROE) is -0.69 and return on invested capital (ROIC) is -71.60%.

The current PE Ratio of {name} is {pe}. {name}’s PEG ratio is {priceToEarningsGrowthRatio}.

In the last 12 months, Bioline Rx had revenue of 28.94M and earned -9.22M in profits. Earnings per share was -0.01.

In the last 12 months, operating cash flow was -32.35M and capital expenditures -21.00K, giving a free cash flow of -32.38M billion.

Bioline Rx pays an annual dividend of ―, resulting in a dividend yield of ―

Bioline Rx upcoming earnings date is Aug 13, 2025, Before Open (Confirmed).

Bioline Rx as a current ratio of 1.76, with Debt / Equity ratio of 65.87%

In the past 12 months, Bioline Rx has paid 0.00 in taxes.

Bioline Rx EV to EBITDA ratio is 6.63, with an EV/FCF ratio of -0.59.

Bioline Rx has 26.37M in cash and marketable securities with $13.74M in debt, giving a net cash position of -12.63M billion.

Gross margin is 64.90%, with operating margin of -70.52%, and net profit margin of -31.86%.

The average price target for Bioline Rx is ―, which is 11.43% higher than the current price. The consensus rating is ―